Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at a new drug called olaparib for leukaemia and mantle cell lymphoma that has stopped responding to treatment (PICLLE)

Overview

Cancer types:

Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)

Status:

Results

Phase:

Phase 1/2

Details

The trial team wanted to find the best dose of olaparib to treat leukaemia and lymphoma and if it might help people live longer. It was open to people with:

  • chronic lymphocytic leukaemia (CLL)

  • T-prolymphocytic leukaemia (T-PLL)

  • mantle cell lymphoma

Recruitment start: 13 July 2011

Recruitment end: 23 January 2015

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Guy Pratt

Supported by

AstraZeneca

Bloodwise

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

University of Birmingham

Last reviewed: 25 Jan 2019

CRUK internal database number: 7447

Help and support